MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss and
comprehensive loss
-$160,416K
Loss from operations
-$160,416K
Total operating
expenses
$160,416K
General and
administrative
$157,870K
Research and development
$2,546K
Back
Back
Income Statement
source: myfinsight.com
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)